Growing demand for personalized medicine across the globe to drive the growth of global cell & gene therapy cold chain logistics market.
According to TechSci Research report, “Cell & Gene Therapy Cold Chain Logistics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2017-2027”, the global cell & gene therapy cold chain logistics market stood at USD 1316.93 Million in 2021 and is expected to grow at a steady CAGR of 14.29% during the forecast period on account of rising demand for personalized treatment across the globe.
The global cell & gene therapy cold chain logistics market is expected to grow at a robust rate during the forecast period on account of increasing R&D activities related to production of cell & gene therapy products by major companies around the globe. Additionally, many players who are operating in the healthcare industry or cell & gene therapy development industry have started entering into the cell & gene therapy cold chain logistics industry as well.
These companies are either developing different products or solutions required for storage and preserving cell & gene therapy products in cold chain or are opening their own cold chain solutions or the bigger players are acquiring the existing small players or entering into partnerships & agreements, thereby creating opportunities for overall market growth. For instance, Catalent, Inc, in June 2021, added cryogenic capabilities to its 200,000 square foot facility in Philadelphia.
Additionally due to personalized nature of some products, the task at hand is to comprehend each component of this supply chain, as well as their specific requirements. Transportation of gene treatments in situations other than those required for specific purposes can stifle industry expansion. Growth.
Browse over 182 market data Figures and 10 market data Tables spread through 300 Pages and an in-depth TOC on "Global Cell & Gene Therapy Cold Chain Logistics Market"
The global cell & gene therapy cold chain logistics market is segmented based on component, services offered, mode of transportation, holding temperature range, end user, and regional distribution.
Based on component, the market can be split into cryogenic shippers, cryogenic storage freezers, ultra-low freezers, cold chain management systems, shipment, and storage medium, cryogenic packout kits, others. The cryogenic shippers are expected to dominate the market during forecast period.
Based on services offered, the market can be divided into transportation, storage, packaging. Transportation segment dominated the market as the biopharma logistics companies offer various services, and transportation is one of the majorly offered key services being taken by the pharmaceutical companies.
As the biopharmaceutical sector is increasing its dominance globally, logistics companies tend to add other value-added services as well, which mainly comprises storage and packaging. Packaging and storage require specific cold chain maintenance systems as well as refrigerated and cryogenic shippers.
Hence, companies are moving forward to add other services on their portal along with transportation to emerge in the competitive world. In terms of mode of transportation, the market is divided into air, ground, water. Air transportation is one of the most preferred modes of supply chain logistics market in the cell and gene therapy segment.
It offers a quick, more reliable, and equipped source to transfer the cell and gene therapy samples in short deadlines. Ground or road transport is also growing substantially to meet the increasing consumer needs and requirements. For inter- and intra-state shipments, road transport is preferred as it is a cost-effective and prominent mode of delivery.
Download Sample Report @ https://www.techsciresearch.com/sample-report.aspx?cid=8289
Customers can also request for 10% free customization on this report.
In terms of holding temperature range, the market can be categorized into cryogenic, refrigerated, ambient, others Cryogenic shippers provide a safe and convenient method of shipping cell and gene therapy products. These shippers are designed with anterior walls to hold a cooling medium and the product is stored in an interior chamber. They usually come in a variety of sizes, with various options for shipment of approximately 1000 vials or less, depending upon the size of the container.
These shippers comply with numerous flight regulations, and they could be handled by major flight carriers. Ultra-low freezers are mechanical freezers capable of maintaining temperature approximately -150 degrees Celsius. The major function of these components is to store and deliver the cell and gene therapy products while maintaining their viability.
Based on end user, the market can be segmented into pharmaceutical & biotechnology companies, academic & research institutes, others. Pharmaceutical and biotechnology companies is the leading segment amongst all due to capital investments, government support as well as regulations. These pharmaceutical and biotechnology companies aim to develop therapies and sell them across the world. These biotechnology firms have the capacity to deliver quality care and medical requirements as per the latest innovation and technology developed by them.
Key market players in the cell & gene therapy cold chain logistics market include:
- AmerisourceBergen Corporation (World Courier)
- United Parcel Service (Marken)
- Catalent, Inc.
- BioLife Solutions, Inc.
- Cryoport, Inc.
- Atelerix Ltd.
- Biostor Ireland Ltd
- Thermo Fischer Scientific, Inc.
- Life Science Group Ltd (LSG)
- Yourway Biopharma Services Company
- Bertelsmann SE & Co. KGaA (Arvato Supply Chain Solutions)
- Be The Match Biotherapies
Additionally, there are other other prominent players operating in the market include Catalent, Inc., BioLife Solutions, Inc., Cryoport, Inc., among others, holding a significant position in the global cell & gene therapy cold chain logistics market. The companies are adopting innovative technique to compete in the market. various companies operating in the market are following strategies like mergers & acquisitions, collaborations & partnerships, and new product launches to stay competitive and have an edge over the other players operating in the industry.
“Asia Pacific is expected to be the fastest growing region in global cell & gene therapy cold chain logistics market during forecast years since China is the major center of research for the research and development of cell and gene therapy, hence witnesses a great demand for the cell and gene therapy cold chain logistics market. Additionally, China ranks second after the United States in the global cell therapy manufacturing market. Between 2017 and 2019, the Chinese government granted thousands of patents related to cell and gene therapy, and around 1000 clinical trials were either conducted or were underway during this period. Additionally, the expansion of Showa Denko’s Minaris in Japan adjacent to its existing site in Yokohama will further open up new opportunities for the growth of cell therapy manufacturing in the country and the Asia Pacific region. Minaris will be investing about USD23.8 million in building this 43,056-square-feet new facility. there will be additional demand of Cell & gene therapy which can witness the phenomenal demand for these cell & gene therapy cold chain logistics in the coming days.” said Mr. Karan Chechi, Research Director with TechSci Research, a research based Global management consulting firm.
“Global Cell & Gene Therapy Cold Chain Logistics Market By Component (Cryogenic Shippers, Cryogenic Storage Freezers, Ultra Low Freezers, Cold Chain Management Systems, Shipment and Storage Medium, Cryogenic Packout Kits, Others), By Services Offered (Transportation, Storage, Packaging) By Mode of Transportation (Air, Ground, Water), By Holding Temperature Range (Cryogenic, Refrigerated, Ambient, Others), By End User (Pharmaceutical & Biotechnology Companies, Academic & Research Institutes, Others), By Region, Forecast & Opportunities, 2025”,” has evaluated the future growth potential of global cell & gene therapy cold chain logistics market and provides statistics & information on market size, structure and future market growth. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment decisions. Besides, the report also identifies and analyzes the emerging trends along with essential drivers, challenges, and opportunities in global cell & gene therapy cold chain logistics market.
Browse Related Reports:
Global CAR-T Cell Therapy Market, By Product Type (Yescarta, Kymriah (Tisagenlecleucel), Tecartus (brexucabtagene autoleucel), Breyanzi (lisocabtagene maraleucel), Abecma (idecabtagene vicleucel), Others), By Tumor Type (Hematological Malignancies, Solid Tumors), By Indication (DLBCL, ALL, FL, MCL, Others), By Treatment Type (Single Treatment, Combination Treatment), By Targeted Antigen (CD 19, BCMA (B-Cell Maturation Antigen), Others), By End User (Hospitals, Speciality Clinics, Ambulatory Surgical Centers, Others), By Region, Competition Forecast & Opportunities, 2026
Cell Therapy Manufacturing Market - Global Industry Size, Share, Trends, Competition, Opportunity, and Forecast, 2016-2026 Segmented By Therapy (T-Cell Therapies, Dendritic Cell Therapies, Tumor Cell Therapies, Stem Cell Therapies), By Source of Cell (Autologous v/s Allogenic), By Scale of Operation (Preclinical, Clinical, Commercial), By Source (In-House v/s Contract Manufacturing), By Application (Oncology, Cardiovascular Diseases, Orthopedic Diseases, Others), By End User (Pharmaceutical & Biotechnology Companies, Academic & Research Institutes, Others)
Mr. Ken Mathews
708 Third Avenue,
New York – 10017
Email: [email protected]
For More Market Research Blogs Visit: https://techsciblog.com/